EndoPredict(®) in early hormone receptor-positive, HER2-negative breast cancer

PURPOSE: Evaluating consecutive early breast cancer patients, we analyzed both the impact of EndoPredict(®) on clinical decisions as well as clinico-pathological factors influencing the decision to perform this gene expression test. METHODS: Hormone receptor (HR)-positive and human epidermal growth...

Descripción completa

Detalles Bibliográficos
Autores principales: Almstedt, K., Mendoza, S., Otto, M., Battista, M. J., Steetskamp, J., Heimes, A. S., Krajnak, S., Poplawski, A., Gerhold-Ay, A., Hasenburg, A., Denkert, C., Schmidt, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275019/
https://www.ncbi.nlm.nih.gov/pubmed/32436145
http://dx.doi.org/10.1007/s10549-020-05688-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275019/
https://www.ncbi.nlm.nih.gov/pubmed/32436145
http://dx.doi.org/10.1007/s10549-020-05688-1

Ejemplares similares